Cellectis announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its allogeneic CAR-T therapy candidate, lasmecabtagene timgedleucel (lasme-cel), for treating relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). This designation recognizes the potential of lasme-cel to address significant unmet medical needs in these patients, supported by promising Phase 1 trial data showing efficacy and manageable safety. The pivotal Phase 2 trial, BALLI-01, is currently open for enrollment, with final Phase 1 data to be presented at the 2026 European Hematology Association Congress. This RMAT status may accelerate regulatory review and development, advancing lasme-cel toward potential approval.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
